What's Happening?
The U.S. Food and Drug Administration (FDA) has approved Freenome's SimpleScreen CRC, a blood-based screening test for colorectal cancer (CRC) in adults aged 45 and older who are at average risk. This test, which will be commercialized by Abbott in the
U.S., offers a new option for CRC screening that requires only a simple blood draw. The approval follows extensive clinical research and collaboration, including the PREEMPT CRC study, which enrolled over 48,000 participants. SimpleScreen CRC demonstrated 81.1% sensitivity in detecting colorectal cancer and 90.4% specificity for advanced colorectal neoplasia. The test aims to increase screening rates among the estimated 60 million Americans overdue for CRC screening.
Why It's Important?
Colorectal cancer is a leading cause of cancer-related deaths in the U.S., yet it is highly preventable and treatable when detected early. The approval of SimpleScreen CRC provides a less invasive screening option, potentially increasing participation rates among those who avoid traditional methods like colonoscopy. This could lead to earlier detection and improved outcomes, reducing the mortality rate associated with CRC. The test's integration into Medicare coverage and expected inclusion in American Cancer Society guidelines further supports its accessibility and adoption, potentially transforming CRC screening practices.
What's Next?
With FDA approval, SimpleScreen CRC is set to be commercialized by Abbott, expanding its CRC screening portfolio. The test will be incorporated into the American Cancer Society guidelines, enhancing its reach. Freenome plans to integrate SimpleScreen CRC into its broader SimpleScreen portfolio, advancing additional cancer tests. The company will receive a $100 million milestone payment from Abbott, supporting further development and commercialization efforts. The focus will be on increasing screening participation and improving early detection rates, ultimately aiming to reduce CRC-related deaths.
